Skip to main content

Major hep B players Gilead and Vir join forces to find a cure A Fiercebiotech article


 Gilead Sciences and trendy biotech Vir Biotechnology are teaming up in the effort to find a cure to the liver disease hepatitis B.

Gilead already has vast experience in hepatitis C, producing drugs and combos a few years back that essentially cured the disease. Now, it’s working its way through the alphabet, penning a deal late last year in hepatitis D and now signing up with Vir for hepatitis B (HBV) in the hope of bettering its already marketed HBV meds.

Current HBV treatments may suppress viral replication, but they do not completely clear out the virus; the infection’s covalently closed circular DNA, or cccDNA, enables HBV replication to restart if treatment is stopped.


Vir is hoping to put an end to that and has already teamed up with Alnylam. Back in the summer, the companies unveiled a peek at their ongoing phase 2 of RNA hopeful VIR-2218 in patients with chronic HBV on nucleotide/nucleoside reverse transcriptase inhibitors, the current standard of care.

Their therapy is designed to target a conserved region in the HBV X gene. This drug, originally called ALN-HBV-02 before Alnylam licensed it to Vir in 2017, came as part of an infectious disease deal worth up to $1 billion.


VIR-2218 is designed to silence all HBV transcripts, from both cccDNA and integrated DNA, across all 10 HBV genotypes, and it showed broadly positive results last year.

Gilead, meanwhile, sells HBV treatments Viread (tenofovir disoproxil fumarate) and Vemlidy (tenofovir alafenamide).

But under the new deal, Gilead will wed its investigational TLR-8 agonist selgantolimod to VIR-2218, as well as a "marketed PD-1 antagonist"—though they didn’t say which one—in HBV patients both who have had treatments and who have not. Gilead adds that under the phase 2 planned for the combo, its therapy Vemlidy may also be offered to those who have already had treatment before.

The hope is that combining an immunomodulation drug alongside an antigen suppression therapy will lead to a functioning cure for the disease.

This isn’t the first time Gilead has gunned for a cure, penning a $445 million deal with Precision Biosciences using a gene therapy approach. Two years down the line in 2020, however, Gilead pulled out of the deal without explanation. It will hope to have more luck with Vir.


“We are enthusiastic about this collaboration,” said Phil Pang, M.D., Ph.D., chief medical officer at Vir. “We believe a functional cure for the majority of patients will require a reduction of the levels of circulating viral proteins together with an immune boost to stimulate the production of new T-cells that can bring the infection under control. We believe that this collaboration with Gilead adds a novel and significant new combination to our efforts to find a cure for HBV.”

HBV affects more than 290 million people worldwide, with around 800,000 people estimated to die of HBV-related liver disease.

Financial terms were not disclosed.


https://www.fiercebiotech.com/biotech/major-hep-b-players-gilead-and-vir-join-forces-to-find-a-cure

Comments

Popular posts from this blog

Can We Make A Vaccine Against Smoking?

  This segment sounds good but we need to be careful here or we end up where we started in 2021 vaccines becoming political. 

Texas governor bans vaccine passports from being required in state ABC News

  Thats Right States like Texas and Florida got the Vaccine Passport Conspiracy from Del Bigtree.  https://abc7.com/politics/texas-governor-bans-vaccine-passport-requirement-in-state/10491161/ AUSTIN, Texas -- Gov. Greg Abbott issued an executive order Tuesday morning prohibiting state agencies or political subdivisions in Texas from creating a "vaccine passport" requirement. Conversation has grown around  vaccine passports recently as an option that can be used for travel or even eating out . They are typically described as an app with a code that verifies if someone has been vaccinated or recently tested negative for COVID-19. They're already in use in Israel, and in development in parts of Europe. But Abbott shut that down as an option in the Lone Star State with Executive Order No. GA - 35 also prohibiting "organizations receiving public funds from requiring consumers to provide documentation of vaccine status in order to receive any service or enter any place....

Anti-Vax Conspiracies strike back in the USA July 2021 Original Article

 Thumbnail credit by Jeff Holiday Production In the past few weeks the anti-vax lobby has ratcheted up the ante on their lobbying efforts. The event that kicked off this new wave of anti-vax scares was the "Knock on the Door rants" according to the Washington Post on a July 9th article they cited  rants by Marjorie Taylor Greene and Laurent Boebert in a political rally that sparked the scare. "Rep. Marjorie Taylor Greene (R-Ga.) got the ball rolling Tuesday by comparing the effort to “ medical brown shirts showing up at their door ordering vaccinations .” Not to be outdone, Rep. Lauren Boebert (R-Colo.) took to Twitter the next day to offer her own Nazi comparison, labeling the door-knockers “ needle Nazis .” If anyone should know the folly of such metaphors, it would seem to be Greene, who just three weeks prior conceded in an apology after another wayward Nazi/coronavirus comment that “ there is no comparison to the Holocaust .” And it’s worth emphasizing that there is...